STAT10d
Sales of GSK’s RSV vaccine down dramatically from last year
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
BioPharma Dive10d
GSK vaccine sales sink on lower demand for RSV, shingles shots
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand
GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
FiercePharma10d
GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
Taiwan News11d
AIM Vaccine’s heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval
HONG KONG SAR - Newswire - 30 October 2024 - AIM Vaccine (06660.HK), the leader in Chinese mRNA vaccines, announced on 30 th October that mRNA respiratory syncytial virus (RSV) vaccine developed by a ...
Yahoo Finance11d
GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand
(Reuters) -GSK (GSK) on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...